Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

RAS-mediated oncogenic signaling pathways in human malignancies

Khan, Abdul Q., Kuttikrishnan, Shilpa, Siveen, Kodappully S., Prabhu, Kirti S., Shanmugakonar, Muralitharan, Al- Naemi, Hamda A., Haris, Mohammad, Dermime, Said, Uddin, Shahab · 2019 · Seminars in Cancer Biology

Abstract

Abnormally activated RAS proteins are the main oncogenic driver that governs the functioning of major signaling pathways involved in the initiation and development of human malignancies. Mutations in RAS genes and or its regulators, most frequent in human cancers, are the main force for incessant RAS activation and associated pathological conditions including cancer. In general, RAS is the main upstream regulator of the highly conserved signaling mechanisms associated with a plethora of important cellular activities vital for normal homeostasis. Mutated or the oncogenic RAS aberrantly activates a web of interconnected signaling pathways including RAF-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase), phosphoinositide-3 kinase (PI3K)/AKT (protein kinase B), protein kinase C (PKC) and ral guanine nucleotide dissociation stimulator (RALGDS), etc., leading to uncontrolled transcriptional expression and reprogramming in the functioning of a range of nuclear and cytosolic effectors critically associated with the hallmarks of carcinogenesis. This review highlights the recent literature on how oncogenic RAS negatively use its signaling web in deregulating the expression and functioning of various effector molecules in the pathogenesis of human malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2018.03.001

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 207

  1. Rojas, 2012, The Ras protein superfamily: evolutionary tree and role of conserved amino acids, J. Cell Biol., 196, 189, 10.1083/jcb.201103008 · DOI · Paper page
  2. Wennerberg, 2005, The Ras superfamily at a glance, J. Cell Sci., 118, 843, 10.1242/jcs.01660 · DOI · Paper page
  3. Ward, 2012, Targeting oncogenic Ras signaling in hematologic malignancies, Blood, 120, 3397, 10.1182/blood-2012-05-378596 · DOI · Paper page
  4. Vigil, 2010, Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy, Nat. Rev. Cancer, 10, 842, 10.1038/nrc2960 · DOI · Paper page
  5. Zhou, 2016, The role of wild type RAS isoforms in cancer, Semin. Cell Dev. Biol., 58, 60, 10.1016/j.semcdb.2016.07.012 · DOI · Paper page
  6. Mann, 2016, KRAS-related proteins in pancreatic cancer, Pharmacol. Ther., 168, 29, 10.1016/j.pharmthera.2016.09.003 · DOI · Paper page
  7. LeBleu, 2013, Origin and function of myofibroblasts in kidney fibrosis, Nat. Med., 19, 1047, 10.1038/nm.3218 · DOI · Paper page
  8. Logsdon, 2016, The significance of Ras activity in pancreatic cancer initiation, Int. J. Biol. Sci., 12, 338, 10.7150/ijbs.15020 · DOI
  9. Baines, 2011, Inhibition of Ras for cancer treatment: the search continues, Future Med. Chem., 3, 1787, 10.4155/fmc.11.121 · DOI · Paper page
  10. Rodenhuis, 1992, Ras and human tumors, Semin. Cancer Biol., 3, 241
  11. Mengoli, 2016, K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: report of two cases and review of the literature, Lung Cancer, 93, 55, 10.1016/j.lungcan.2016.01.002 · DOI
  12. Beaupre, 1999, RAS and leukemia: from basic mechanisms to gene-directed therapy, J. Clin. Oncol., 17, 1071, 10.1200/JCO.1999.17.3.1071 · DOI · Paper page
  13. Bahrami, 2018, The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer, J. Cell. Physiol., 233, 2162, 10.1002/jcp.25952 · DOI
  14. Martinelli, 2017, Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK, Cancer Treat. Rev., 53, 61, 10.1016/j.ctrv.2016.12.001 · DOI
  15. Coelho, 2017, Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA, Immunity, 47, 1083, 10.1016/j.immuni.2017.11.016 · DOI · Paper page
  16. Chin, 1999, Essential role for oncogenic Ras in tumour maintenance, Nature, 400, 468, 10.1038/22788 · DOI · Paper page
  17. Knickelbein, 2015, Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer, Genes Dis., 2, 4, 10.1016/j.gendis.2014.10.002 · DOI
  18. Barbacid, 1987, Ras genes, Annu. Rev. Biochem, 56, 779, 10.1146/annurev.bi.56.070187.004023 · DOI · Paper page
  19. Cohen, 1989, Expression of the H-ras proto-oncogene is controlled by alternative splicing, Cell, 58, 461, 10.1016/0092-8674(89)90427-3 · DOI
  20. Seeburg, 1984, Biological properties of human c-Ha-ras1 genes mutated at codon 12, Nature, 312, 71, 10.1038/312071a0 · DOI · Paper page
  21. Bos, 1989, Ras oncogenes in human cancer: a review, Cancer Res., 49, 4682
  22. Parsons, 2002, Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression, Carcinogenesis, 23, 943, 10.1093/carcin/23.6.943 · doi:10.1093/carcin/23.6.943
  23. Smith, 2010, Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours–implications for personalised cancer medicine, Br. J. Cancer, 102, 693, 10.1038/sj.bjc.6605534 · DOI · Paper page
  24. Johnson, 2001, Somatic activation of the K-ras oncogene causes early onset lung cancer in mice, Nature, 410, 1111, 10.1038/35074129 · DOI · Paper page
  25. Stolze, 2015, Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines, Sci. Rep., 5, 8535, 10.1038/srep08535 · DOI
  26. Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers, Br. J. Cancer, 108, 1757, 10.1038/bjc.2013.118 · DOI · Paper page
  27. Imamura, 2012, Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers, Clin. Cancer Res., 18, 4753, 10.1158/1078-0432.CCR-11-3210 · DOI · Paper page
  28. Edkins, 2006, Recurrent KRAS codon 146 mutations in human colorectal cancer, Cancer Biol. Ther., 5, 928, 10.4161/cbt.5.8.3251 · DOI · Paper page
  29. Omholt, 2002, Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression, Clin. Cancer Res., 8, 3468
  30. Irahara, 2010, NRAS mutations are rare in colorectal cancer, Diagn. Mol. Pathol., 19, 157, 10.1097/PDM.0b013e3181c93fd1 · DOI · Paper page
  31. Matsumoto, 1997, Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton, Oncogene, 15, 2409, 10.1038/sj.onc.1201416 · DOI
  32. Huff, 1997, R-Ras is regulated by activators and effectors distinct from those that control Ras function, Oncogene, 14, 133, 10.1038/sj.onc.1200815 · DOI
  33. Fernandez-Medarde, 2011, Ras in cancer and developmental diseases, Genes Cancer, 2, 344, 10.1177/1947601911411084 · DOI · Paper page
  34. Caldas, 1994, Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia, Cancer Res., 54, 3568
  35. Lu, 2017, Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas, PLoS One, 12, e0181532, 10.1371/journal.pone.0181532 · DOI
  36. Lee, 2016, KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis, SpringerPlus, 5, 1172, 10.1186/s40064-016-2847-4 · DOI
  37. Hashimoto, 2016, Heterogeneity of KRAS mutations in pancreatic ductal adenocarcinoma, Pancreas, 45, 1111, 10.1097/MPA.0000000000000624 · DOI
  38. Miglio, 2014, KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance, Pathol. Res. Pract., 210, 307, 10.1016/j.prp.2014.01.011 · DOI
  39. Sinn, 2014, KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma, Pancreas, 43, 578, 10.1097/MPA.0000000000000077 · DOI
  40. Forbes, 2011, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer, Nucleic Acids Res., 39, D945, 10.1093/nar/gkq929 · DOI · Paper page
  41. Immervoll, 2006, Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes, Virchows Arch., 448, 788, 10.1007/s00428-006-0191-8 · DOI
  42. Kawesha, 2000, K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma, Int. J. Cancer, 89, 469, 10.1002/1097-0215(20001120)89:6<469::AID-IJC1>3.0.CO;2-L · DOI
  43. Whyte, 1997, K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors, J. Biol. Chem., 272, 14459, 10.1074/jbc.272.22.14459 · DOI · Paper page
  44. Weden, 2011, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras, Int. J. Cancer, 128, 1120, 10.1002/ijc.25449 · DOI · Paper page
  45. Poulin, 2017, No back seat for a progression event-K-RAS as a therapeutic target in CRC, Genes Dev., 31, 333, 10.1101/gad.297630.117 · DOI
  46. Abubaker, 2009, Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma, J. Pathol., 219, 435, 10.1002/path.2625 · DOI
  47. Lievre, 2018, RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: a status report in 2014, Dig. Liver Dis., 10.1016/j.dld.2017.12.029 · DOI
  48. Petaccia de Macedo, 2017, KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care, Am. J. Cancer. Res., 7, 1978
  49. Zekri, 2017, Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes, Genet. Mol. Res., 16, 10.4238/gmr16019369 · DOI
  50. Kafatos, 2017, RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data, Biomark. Med., 10.2217/bmm-2016-0358 · DOI
  51. Vogelstein, 1988, Genetic alterations during colorectal-tumor development, N. Engl. J. Med., 319, 525, 10.1056/NEJM198809013190901 · DOI · Paper page
  52. Chang, 2016, Mutation spectra of RAS gene family in colorectal cancer, Am. J. Surg., 212, 537, 10.1016/j.amjsurg.2016.02.013 · DOI
  53. Conlin, 2005, The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma, Gut, 54, 1283, 10.1136/gut.2005.066514 · DOI · Paper page
  54. Dinu, 2014, Prognostic significance of KRAS gene mutations in colorectal cancer–preliminary study, J. Med. Life, 7, 581
  55. Lohinai, 2017, KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis, Sci. Rep., 7, 39721, 10.1038/srep39721 · DOI
  56. Cejas, 2009, KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis, PLoS One, 4, e8199, 10.1371/journal.pone.0008199 · DOI
  57. Lievre, 2008, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J. Clin. Oncol., 26, 374, 10.1200/JCO.2007.12.5906 · DOI · Paper page
  58. Raponi, 2008, KRAS mutations predict response to EGFR inhibitors, Curr. Opin. Pharmacol., 8, 413, 10.1016/j.coph.2008.06.006 · DOI
  59. Saif, 2009, Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas, Cancer J., 15, 339, 10.1097/PPO.0b013e3181b36264 · DOI
  60. Howell, 2013, RAS mutations in thyroid cancer, Oncologist, 18, 926, 10.1634/theoncologist.2013-0072 · DOI · Paper page
  61. Bhaijee, 2011, Molecular analysis of thyroid tumors, Endocr. Pathol., 22, 126, 10.1007/s12022-011-9170-y · DOI
  62. Abubaker, 2008, Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population, J. Clin. Endocrinol. Metab., 93, 611, 10.1210/jc.2007-1717 · DOI · Paper page
  63. Latteyer, 2016, Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer, Endocrine, 54, 733, 10.1007/s12020-016-1080-9 · doi:10.1007/s12020-016-1080-9
  64. Duman, 2014, Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma, Contemp. Oncol. (Pozn.), 18, 234
  65. Fakhruddin, 2017, BRAF and NRAS mutations in papillary thyroid carcinoma and concordance in BRAF mutations between primary and corresponding lymph node metastases, Sci. Rep., 7, 4666, 10.1038/s41598-017-04948-3 · doi:10.1038/s41598-017-04948-3
  66. Wells, 2009, Targeting the RET pathway in thyroid cancer, Clin. Cancer Res., 15, 7119, 10.1158/1078-0432.CCR-08-2742 · DOI · Paper page
  67. Lee, 2010, Complications of radioactive iodine treatment of thyroid carcinoma, J. Natl. Compr. Cancer Netw., 8, 1277, 10.6004/jnccn.2010.0094 · DOI
  68. Hong, 2009, Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies, Clin. Cancer Res., 15, 7061, 10.1158/1078-0432.CCR-09-1241 · DOI
  69. Reuter, 2000, Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies, Blood, 96, 1655, 10.1182/blood.V96.5.1655 · DOI · Paper page
  70. Wang, 2010, Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia, Blood, 116, 5991, 10.1182/blood-2010-04-281527 · DOI
  71. Zhou, 2017, KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia, Oncotarget, 8, 66087, 10.18632/oncotarget.19798 · DOI
  72. Liang, 2018, Mutational status of NRAS, KRAS, and PTPN 11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia, Pediatr. Blood Cancer, 65, 10.1002/pbc.26786 · DOI
  73. De Melo, 1997, N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis, Leuk. Lymphoma, 24, 309, 10.3109/10428199709039018 · DOI
  74. Kiyoi, 1999, Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia, Blood, 93, 3074
  75. Shih, 2004, Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia, Leukemia, 18, 466, 10.1038/sj.leu.2403274 · DOI
  76. Lubbert, 1990, N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis, Blood, 75, 1163, 10.1182/blood.V75.5.1163.1163 · DOI
  77. Paquette, 1993, N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome, Blood, 82, 590, 10.1182/blood.V82.2.590.590 · DOI · Paper page
  78. Marin, 2010, Current status of imatinib as frontline therapy for chronic myeloid leukemia, Semin. Hematol., 47, 312, 10.1053/j.seminhematol.2010.06.003 · DOI
  79. Timar, 2014, The clinical relevance of KRAS gene mutation in non-small-cell lung cancer, Curr. Opin. Oncol., 26, 138, 10.1097/CCO.0000000000000051 · DOI
  80. Suzuki, 1990, Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products, Oncogene, 5, 1037
  81. Marabese, 2015, KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy, Oncotarget, 6, 34014, 10.18632/oncotarget.5607 · DOI
  82. Forest, 2017, EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: value of testing on samples with poor specimen adequacy and analysis of discrepancies, Exp. Mol. Pathol., 103, 306, 10.1016/j.yexmp.2017.11.013 · DOI
  83. Jia, 2017, Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer, Oncol. Lett., 14, 6525
  84. Turhal, 2015, Prevalence of K-Ras mutations in hepatocellular carcinoma: a Turkish Oncology Group pilot study, Mol. Clin. Oncol., 3, 1275, 10.3892/mco.2015.633 · DOI
  85. Ye, 2014, Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice, Oncogene, 33, 5133, 10.1038/onc.2013.468 · DOI
  86. Hou, 2014, Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma, Oncol. Lett., 8, 1249, 10.3892/ol.2014.2253 · DOI
  87. Tilch, 2014, Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women, Breast Cancer Res. Treat., 143, 385, 10.1007/s10549-013-2798-1 · DOI
  88. Cejalvo, 2016, Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer, Breast Cancer Res. Treat., 160, 69, 10.1007/s10549-016-3980-z · DOI
  89. Wang, 2015, Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai, Genet. Mol. Res., 14, 14840, 10.4238/2015.November.18.49 · DOI
  90. Uvirova, 2015, Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 159, 466, 10.5507/bp.2015.029 · doi:10.5507/bp.2015.029
  91. Xing, 2017, Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma, Hum. Pathol., 68, 87, 10.1016/j.humpath.2017.08.021 · doi:10.1016/j.humpath.2017.08.021
  92. Zannoni, 2016, Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients, J. Clin. Pathol., 69, 1088, 10.1136/jclinpath-2016-203776 · DOI
  93. Nanus, 1990, Infrequent ras oncogene point mutations in renal cell carcinoma, J. Urol., 143, 175, 10.1016/S0022-5347(17)39905-6 · DOI
  94. Ponti, 2017, BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival, Anticancer Res., 37, 7043
  95. Munoz-Couselo, 2017, NRAS-mutant melanoma: current challenges and future prospect, Onco Targets Ther., 10, 3941, 10.2147/OTT.S117121 · DOI · Paper page
  96. Queirolo, 2017, Binimetinib for the treatment of NRAS-mutant melanoma, Expert Rev. Anticancer Ther., 17, 985, 10.1080/14737140.2017.1374177 · DOI
  97. Heppt, 2017, Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care, BMC Cancer, 17, 536, 10.1186/s12885-017-3529-5 · DOI
  98. McDaniel, 2014, HRAS mutations are frequent in inverted urothelial neoplasms, Hum. Pathol., 45, 1957, 10.1016/j.humpath.2014.06.003 · DOI
  99. Beukers, 2014, HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome, Eur. J. Hum. Genet., 22, 837, 10.1038/ejhg.2013.251 · doi:10.1038/ejhg.2013.251
  100. Wang, 2012, H-ras mutation detection in bladder cancer by COLD-PCR analysis and direct sequencing, Urol. Int., 88, 350, 10.1159/000336132 · DOI
  101. Jinesh, 2017, Molecular genetics and cellular events of K-Ras-driven tumorigenesis, Oncogene
  102. Fey, 2016, The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells, Semin. Cell Dev. Biol., 58, 96, 10.1016/j.semcdb.2016.06.011 · DOI
  103. Yang, 2017, Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma, Oncol. Lett., 13, 1041, 10.3892/ol.2017.5557 · DOI · Paper page
  104. Cseh, 2014, “RAF” neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway, FEBS Lett., 588, 2398, 10.1016/j.febslet.2014.06.025 · DOI
  105. Imperial, 2017, Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: its clinical implications, Semin. Cancer Biol.
  106. Dorard, 2017, Deciphering the RAS/ERK pathway in vivo, Biochem. Soc. Trans., 45, 27, 10.1042/BST20160135 · DOI
  107. Sriskanthadevan-Pirahas, 2018, Ras/ERK-signalling promotes tRNA synthesis and growth via the RNA polymerase III repressor Maf1 in Drosophila, PLoS Genet., 14, e1007202, 10.1371/journal.pgen.1007202 · DOI
  108. Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969 · DOI · Paper page
  109. Sheridan, 2013, Inhibiting the RAS-PI3K pathway in cancer therapy, Enzymes, 34, 107, 10.1016/B978-0-12-420146-0.00005-6 · DOI
  110. Jankovic, 1996, International conference on chronic myelocytic leukemia: biology and treatment organised by the Scientific Committee of The Israel Society of Hematology, Jerusalem, Israel, 28-31 January 1996, Leukemia, 10, 1667
  111. Li, 2017, R-Ras-Akt axis induces endothelial lumenogenesis and regulates the patency of regenerating vasculature, Nat. Commun., 8, 1720, 10.1038/s41467-017-01865-x · DOI
  112. Gagliardi, 2017, PDK1: at the crossroad of cancer signaling pathways, Semin. Cancer Biol.
  113. Martini, 2014, PI3K/AKT signaling pathway and cancer: an updated review, Ann. Med., 46, 372, 10.3109/07853890.2014.912836 · DOI · Paper page
  114. Guin, 2015, The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer, Acta Pharmacol. Sin., 36, 291, 10.1038/aps.2014.129 · DOI
  115. Suryaraja, 2013, The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner, Cell Death Dis., 4, e565, 10.1038/cddis.2013.91 · DOI
  116. Bee, 2010, Growth and tumor suppressor NORE1A is a regulatory node between Ras signaling and microtubule nucleation, J. Biol. Chem., 285, 16258, 10.1074/jbc.M109.081562 · DOI
  117. Calvisi, 2009, NORE1A tumor suppressor candidate modulates p21CIP1 via p53, Cancer Res., 69, 4629, 10.1158/0008-5472.CAN-08-3672 · DOI
  118. Stacey, 1984, Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein, Nature, 310, 508, 10.1038/310508a0 · DOI · Paper page
  119. McCarthy, 1995, Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes, Genes Dev., 9, 1953, 10.1101/gad.9.16.1953 · DOI · Paper page
  120. Woods, 2001, Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway, Mol. Cell. Biol., 21, 3192, 10.1128/MCB.21.9.3192-3205.2001 · DOI
  121. Dajee, 2002, Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation, Oncogene, 21, 1527, 10.1038/sj.onc.1205287 · DOI
  122. Amin, 2015, Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds, Semin. Cancer Biol., 35, S55, 10.1016/j.semcancer.2015.02.005 · DOI
  123. Chen, 2001, Regulation of glut1 mRNA by hypoxia-inducible factor-1: interaction between H-ras and hypoxia, J. Biol. Chem., 276, 9519, 10.1074/jbc.M010144200 · DOI · Paper page
  124. Blum, 2005, Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death, Cancer Res., 65, 999, 10.1158/0008-5472.999.65.3 · DOI · Paper page
  125. Semenza, 2007, Hypoxia and cancer, Cancer Metastasis Rev., 26, 223, 10.1007/s10555-007-9058-y · DOI · Paper page
  126. Flier, 1987, Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes, Science, 235, 1492, 10.1126/science.3103217 · DOI · Paper page
  127. Shaw, 2006, Glucose metabolism and cancer, Curr. Opin. Cell Biol., 18, 598, 10.1016/j.ceb.2006.10.005 · DOI · Paper page
  128. Lock, 2011, Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation, Mol. Biol. Cell, 22, 165, 10.1091/mbc.e10-06-0500 · DOI · Paper page
  129. Kim, 2011, Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation, J. Biol. Chem., 286, 12924, 10.1074/jbc.M110.138958 · DOI · Paper page
  130. Rak, 2004, Oncogenes and tumor angiogenesis: the question of vascular supply and vascular demand, Semin. Cancer Biol., 14, 93, 10.1016/j.semcancer.2003.09.014 · DOI
  131. Rak, 1995, Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis, Cancer Res., 55, 4575
  132. Kranenburg, 2004, Stimulation of angiogenesis by Ras proteins, Biochim. Biophys. Acta, 1654, 23
  133. Giehl, 2005, Oncogenic Ras in tumour progression and metastasis, Biol. Chem., 386, 193, 10.1515/BC.2005.025 · DOI · Paper page
  134. Campbell, 2004, Oncogenic Ras and its role in tumor cell invasion and metastasis, Semin. Cancer Biol., 14, 105, 10.1016/j.semcancer.2003.09.015 · DOI · Paper page
  135. Nebert, 2002, Transcription factors and cancer: an overview, Toxicology, 181–182, 131, 10.1016/S0300-483X(02)00269-X · DOI
  136. Lee, 2013, Transcriptional regulation and its misregulation in disease, Cell, 152, 1237, 10.1016/j.cell.2013.02.014 · DOI · Paper page
  137. Dolcet, 2005, NF-kB in development and progression of human cancer, Virchows Arch., 446, 475, 10.1007/s00428-005-1264-9 · DOI · Paper page
  138. Tilborghs, 2017, The role of Nuclear Factor-kappa B signaling in human cervical cancer, Crit. Rev. Oncol. Hematol., 120, 141, 10.1016/j.critrevonc.2017.11.001 · DOI · Paper page
  139. Jo, 2000, NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis, Oncogene, 19, 841, 10.1038/sj.onc.1203392 · DOI
  140. Lee, 2006, H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells, Int. J. Cancer, 119, 1767, 10.1002/ijc.22056 · DOI
  141. Sparmann, 2004, Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis, Cancer Cell, 6, 447, 10.1016/j.ccr.2004.09.028 · DOI · Paper page
  142. Meylan, 2009, Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma, Nature, 462, 104, 10.1038/nature08462 · DOI · Paper page
  143. Jeay, 2003, Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B, Mol. Cell. Biol., 23, 2251, 10.1128/MCB.23.7.2251-2263.2003 · DOI
  144. Kim, 2005, NF-kappaB inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation, Carcinogenesis, 26, 1395, 10.1093/carcin/bgi081 · DOI
  145. Mizumoto, 2011, Activation of NF-kappaB is a novel target of KRAS-induced endometrial carcinogenesis, Clin. Cancer Res., 17, 1341, 10.1158/1078-0432.CCR-10-2291 · DOI
  146. Yu, 2014, Revisiting STAT3 signalling in cancer: new and unexpected biological functions, Nat. Rev. Cancer, 14, 736, 10.1038/nrc3818 · DOI · Paper page
  147. Huynh, 2017, The JAK/STAT3 axis: a comprehensive drug target for solid malignancies, Semin. Cancer Biol., 45, 13, 10.1016/j.semcancer.2017.06.001 · DOI · Paper page
  148. Shanmugam, 2016, Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds, Semin. Cancer Biol., 40–41, 35, 10.1016/j.semcancer.2016.03.005 · DOI · Paper page
  149. Zushi, 1998, STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells, Int. J. Cancer, 78, 326, 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4 · doi:10.1002/(sici)1097-0215(19981029)78:3<326::aid-ijc12>3.0.co;2-4
  150. Garcia, 1997, Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells, Cell Growth Differ., 8, 1267
  151. Plaza-Menacho, 2007, Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation, J. Biol. Chem., 282, 6415, 10.1074/jbc.M608952200 · DOI
  152. Tran, 2008, Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas, PLoS One, 3, e2125, 10.1371/journal.pone.0002125 · DOI
  153. Yeh, 2009, Ha-ras oncogene-induced Stat3 phosphorylation enhances oncogenicity of the cell, DNA Cell Biol., 28, 131, 10.1089/dna.2008.0762 · DOI
  154. Gough, 2009, Mitochondrial STAT3 supports Ras-dependent oncogenic transformation, Science, 324, 1713, 10.1126/science.1171721 · DOI · Paper page
  155. Kim, 2009, Targeted disruption of stat3 reveals a major role for follicular stem cells in skin tumor initiation, Cancer Res., 69, 7587, 10.1158/0008-5472.CAN-09-1180 · DOI
  156. Fukuda, 2011, Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression, Cancer Cell, 19, 441, 10.1016/j.ccr.2011.03.002 · DOI · Paper page
  157. Mace, 2015, Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer, Oncotarget, 6, 44509, 10.18632/oncotarget.6332 · DOI
  158. Gough, 2014, STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation, Blood, 124, 2252, 10.1182/blood-2013-02-484196 · DOI
  159. Yu, 2015, Mitochondrial STAT3 contributes to transformation of Barrett’s epithelial cells that express oncogenic Ras in a p53-independent fashion, Am. J. Physiol. Gastrointest. Liver Physiol., 309, G146, 10.1152/ajpgi.00462.2014 · DOI
  160. Saitoh, 2016, STAT3 integrates cooperative Ras and TGF-beta signals that induce Snail expression, Oncogene, 35, 1049, 10.1038/onc.2015.161 · DOI
  161. Yao, 2017, The FOXO 3-FOXM1 axis: a key cancer drug target and a modulator of cancer drug resistance, Semin. Cancer Biol.
  162. Koo, 1819, FOXM1: from cancer initiation to progression and treatment, Biochim. Biophys. Acta, 2012, 28
  163. Kalinichenko, 2015, Is there potential to target FOXM1 for ‘undruggable' lung cancers, Expert Opin. Ther. Targets, 19, 865, 10.1517/14728222.2015.1042366 · DOI
  164. Kopanja, 2015, Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features, J. Hepatol., 63, 429, 10.1016/j.jhep.2015.03.023 · DOI
  165. Pek, 2017, Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer, Oncogene, 36, 4975, 10.1038/onc.2017.120 · DOI · Paper page
  166. Park, 2009, FoxM1, a critical regulator of oxidative stress during oncogenesis, EMBO J., 28, 2908, 10.1038/emboj.2009.239 · DOI · Paper page
  167. Wang, 2014, Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D), Oncogene, 33, 5391, 10.1038/onc.2013.475 · DOI
  168. Eferl, 2003, AP-1: a double-edged sword in tumorigenesis, Nat. Rev. Cancer, 3, 859, 10.1038/nrc1209 · DOI · Paper page
  169. Mechta, 1997, Transformation by ras modifies AP1 composition and activity, Oncogene, 14, 837, 10.1038/sj.onc.1200900 · DOI · Paper page
  170. Zhang, 2017, Oncogenic RAS regulates long noncoding RNA orilnc1 in human cancer, Cancer Res., 77, 3745, 10.1158/0008-5472.CAN-16-1768 · DOI
  171. Cellurale, 2011, Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation, Mol. Cell. Biol., 31, 1565, 10.1128/MCB.01122-10 · DOI
  172. Yoshikawa, 2017, Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1alpha pathway, Cancer Lett., 410, 82, 10.1016/j.canlet.2017.09.017 · DOI
  173. Lim, 2004, Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion, Oncogene, 23, 9427, 10.1038/sj.onc.1208003 · DOI
  174. Zhang, 2017, Transcription factor Etv5 is essential for the maintenance of alveolar type II cells, Proc. Natl. Acad. Sci. U. S. A., 114, 3903, 10.1073/pnas.1621177114 · DOI
  175. Kar, 2013, Molecular mechanisms of ETS transcription factor-mediated tumorigenesis, Crit. Rev. Biochem. Mol. Biol., 48, 522, 10.3109/10409238.2013.838202 · DOI
  176. Zheng, 2013, Oncogene and non-oncogene addiction in inflammation-associated cancers, Future Oncol., 9, 561, 10.2217/fon.12.202 · DOI
  177. Borrello, 2008, Inflammation and cancer: the oncogene-driven connection, Cancer Lett., 267, 262, 10.1016/j.canlet.2008.03.060 · DOI
  178. Kitajima, 2016, Inflammation as a driver and vulnerability of KRAS mediated oncogenesis, Semin. Cell Dev. Biol., 58, 127, 10.1016/j.semcdb.2016.06.009 · DOI
  179. Ancrile, 2008, Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics, Mol. Interv., 8, 22, 10.1124/mi.8.1.6 · DOI
  180. Leibovich-Rivkin, 2014, The inflammatory cytokine TNFalpha cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells, BMC Cancer., 14, 158, 10.1186/1471-2407-14-158 · DOI
  181. Munoz, 2016, Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells, Cancer Biol. Ther., 17, 355, 10.1080/15384047.2016.1139249 · DOI
  182. Catanzaro, 2014, Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4, Nat. Commun., 5, 3729, 10.1038/ncomms4729 · DOI
  183. Giannou, 2017, NRAS destines tumor cells to the lungs, EMBO Mol. Med., 9, 672, 10.15252/emmm.201606978 · DOI
  184. Gstaiger, 2001, Skp2 is oncogenic and overexpressed in human cancers, Proc. Natl. Acad. Sci. U. S. A., 98, 5043, 10.1073/pnas.081474898 · DOI · Paper page
  185. Kulinski, 2017, Dysregulated expression of SKP2 and its role in hematological malignancies, Leuk. Lymphoma, 1
  186. Lee, 2015, Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress, Mol. Cell, 57, 1022, 10.1016/j.molcel.2015.01.015 · DOI
  187. Delogu, 2015, SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice, Oncotarget, 6, 2222, 10.18632/oncotarget.2945 · DOI
  188. Latres, 2001, Role of the F-box protein Skp2 in lymphomagenesis, Proc. Natl. Acad. Sci. U. S. A., 98, 2515, 10.1073/pnas.041475098 · DOI · Paper page
  189. Schepers, 2005, Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway, Exp. Hematol., 33, 747, 10.1016/j.exphem.2005.04.006 · DOI
  190. Batlle, 2017, Cancer stem cells revisited, Nat. Med., 23, 1124, 10.1038/nm.4409 · DOI · Paper page
  191. Siveen, 2017, Targeting acute myeloid leukemia stem cell signaling by natural products, Mol. Cancer, 16, 13, 10.1186/s12943-016-0571-x · DOI · Paper page
  192. Moon, 2014, Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/beta-catenin signaling, J. Natl. Cancer Inst., 106, djt373, 10.1093/jnci/djt373 · DOI · Paper page
  193. Gierut, 2015, Oncogenic K-Ras promotes proliferation in quiescent intestinal stem cells, Stem Cell Res., 15, 165, 10.1016/j.scr.2015.06.003 · DOI
  194. Liu, 2009, p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo, Proc. Natl. Acad. Sci. U. S. A., 106, 19035, 10.1073/pnas.0910009106 · DOI · Paper page
  195. Xu, 2015, Let-7a regulates mammosphere formation capacity through Ras/NF-kappaB and Ras/MAPK/ERK pathway in breast cancer stem cells, Cell Cycle, 14, 1686, 10.1080/15384101.2015.1030547 · DOI
  196. Kim, 2010, Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer, Cancer Lett., 287, 172, 10.1016/j.canlet.2009.06.010 · DOI
  197. Yoon, 2011, The small GTPase Rac1 is involved in the maintenance of stemness and malignancies in glioma stem-like cells, FEBS Lett., 585, 2331, 10.1016/j.febslet.2011.05.070 · DOI
  198. Quinlan, 2008, Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion, Mol. Cell. Biol., 28, 2659, 10.1128/MCB.01661-07 · DOI
  199. Yang, 2008, Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer, PLoS One, 3, e2220, 10.1371/journal.pone.0002220 · DOI
  200. Okada, 2014, Targeting the K-Ras–JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation, Oncotarget, 5, 5100, 10.18632/oncotarget.2087 · DOI

200 of 207 shown

Cited by

See all 179

Metadata

Authors
Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al- Naemi, H. A., Haris, M., Dermime, S., & Uddin, S.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2019-02
Volume
54
Pages
1-13
ISSN
1044-579X (ISSN-L)
OpenAlex
W2793577044
Cited by
179
References
27
FWCI
5.26
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Medical Research Center (16354/16)
  • Hamad Medical Corporation, Doha, State of Qatar

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.